COVID-19 Clinical Algorithms & Resources

Updated 6/16/20
Hydroxychloroquine Emergency Use Authorization Revoked by FDA
The Food and Drug Administration rescinded the emergency use authorization for hydroxychloroquine and chloroquine phosphate as treatments for COVID-19 patients. The FDA stated “the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorized use.” However, clinical trials are not affected and are expected to continue. Read the FDA press release for more information.

Click here to return to the COVID-19 Information & Resources Home Page